ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Ophiopogonin D ameliorates non-alcoholic fatty liver disease in high-fat diet-induced obese mice by improving lipid metabolism, oxidative stress and inflammatory response

Huang, Xi; Ji, Qi; She, Chen-Yi; Cheng, Yi; Zhou, Jian-Rong*; Wu, Qing-Ming*广东省人民医院; 广东省心血管病研究所
Experimental and Therapeutic Medicine2023-9DOI: 10.3892/etm.2023.12116
1被引16阅读
引用收藏
分享

摘要

Lipid metabolic disorders, oxidative stress and inflammation in the liver are key steps in the progression of non-alcoholic fatty liver disease (NAFLD). Ophiopogonin D (OP-D), the main active ingredient of Ophiopogon japonicus, exhibits several pharmacological activities such as antioxidant and anti-inflammatory activities. Therefore, the current study aimed to explore the role of OP-D in NAFLD in a high-fat diet (HFD)-induced obesity mouse model. To investigate the effect of OP-D on NAFLD in vivo, a NAFLD mouse model was established following feeding mice with HFD, then the mice were randomly treated with HFD or HFD + OP-D for 4 weeks. Subsequently, primary mouse hepatocytes were isolated, and enzyme-linked immunosorbent assay, reverse transcription-quantitative PCR western blotting and immunofluorescence analysis were used for assessment to explore the direct effect of OP-D in vitro. The results of the present study indicated that OP-D could ameliorate NAFLD in HFD-induced obese mice by regulating lipid metabolism and antioxidant and anti-inflammatory responses. Additionally, OP-D treatment decreased lipogenesis and inflammation levels in vitro, suggesting that the NF-& kappa;B signaling pathway may be involved in the beneficial effects of OP-D on NAFLD.

学科与关键词

关键词
nonalcoholic fatty liver diseaseophiopogonin Doxidative stressobese miceinflammation
相关
加载中…
  • Nobiletin mitigates NAFLD via lipophagy and inflammation
    Yang, Xushan; Deng, Yudi; Tu, Yali; Feng, Dongliang; Liao, Wenzhen*Food & Function, 2022, 13(19): 10186-10199.被引 6
  • Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro
    Zheng, Yi; Zhao, Jian; Miao, Deyu; Xu, Tingting; Wang, Liziniu; Liu, Changhui; Gao, Yong; Yu, Lili; Shen, Chuangpeng*Biomedicine and Pharmacotherapy, 2023, 164: 114957.被引 1
  • The Role of Ophiopogonin D in Atherosclerosis: Impact on Lipid Metabolism and Gut Microbiota
    Zhang, Ya-Xin; Qu, Shan-Shan; Zhang, Li-Hua; Gu, Yu-Yan; Chen, Yi-Hao; Huang, Zhi-Yong; Liu, Meng-Hua; Zou, Wei; Jiang, Jing; Chen, Jun-Qi*; Wang, Yu-Jue*; Zhou, Feng-Hua*AMERICAN JOURNAL OF CHINESE MEDICINE, 2021, 49(06): 1449-1471.被引 10
查看全部 →

发表信息

论文状态
公开发表
期刊
Experimental and Therapeutic Medicine
发表日期
2023-09
卷期
第 26 卷, 第 3 期
页码
418
DOI
10.3892/etm.2023.12116
语言
ENGLISH
成果收录
SCIE

作者

  • H

    Huang, Xi (第一作者)

    2 · wuhan univ sci & technol

  • J

    Ji, Qi

    2 · wuhan univ sci & technol

查看全部 6 位作者收起作者
  • S

    She, Chen-Yi

    2 · wuhan univ sci & technol

  • C

    Cheng, Yi

  • Z

    Zhou, Jian-Rong (通讯)

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • W

    Wu, Qing-Ming (通讯)

    2 · wuhan univ sci & technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417